HYPERCALCEMIA TREATMENT MARKET ANALYSIS

Hypercalcemia Treatment Market, by Drug Type (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate, and Zoledronic Acid), Calcitonin, Glucocorticoids, Denosumab, Calcimimetics, and Others), by Indication (Primary Hyperthyroidism, Hypercalcemia of Malignancy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI3504
Pages :219
Formats :
Excel and PDF
Industry : Pharmaceutical

Hypercalcemia Treatment MarketSize and Trends

The global hypercalcemia treatment market is estimated to be valued at US$ 3,478.6 million in 2021, and is expected to exhibit a CAGR of 8.1% during the forecast period (2021-2028).

Increasing prevalence of chronic diseases is expected to drive the market growth during the forecast period.

The increasing prevalence of chronic diseases such as cancer is expected to increase the incidence of hypercalcemia, in turn driving the global hypercalcemia treatment market growth in the forecast period. As hypercalcemia may be caused by cancer and other conditions, its increasing prevalence is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention, in 2018, there were 1,708,921 new cancer cases reported in the U.S. and 599,265 people died from cancer.

Increasing research and development activities by the key players is expected to drive the market growth during the forecast period.

The increasing research and development activities related to hypercalcemia treatment by the key players operating in the market is expected to fuel growth of the global hypercalcemia treatment market over the forecast period. For instance, in April, 2019, Kyowa Hakko Kirin Co., Ltd., a Japanese pharmaceutical company, announced that it had submitted a supplemental application to Japan's Ministry of Health, Labor, and Welfare (MHLW) for KHK7580 (evocalcet) for treating hypercalcemia in patients with primary hyperparathyroidism or parathyroid carcinoma. Moreover, this application is based on the preliminary (24-week) results of a phase III study evaluating the efficacy of KHK7580.